Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,426.00    36.00 (1.51%)
Bid:
2,424.00
Ask:
2,426.00
Spread: 2.00 (0.083%)
Market Cap: £7.79b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

24 Oct 2024 07:00

RNS Number : 3430J
Bunzl PLC
24 October 2024
 

24 October 2024

BUNZL Q3 TRADING STATEMENT

IMPROVED UNDERLYING REVENUE GROWTH; FY GUIDANCE UNCHANGED

 

Bunzl plc, the specialist international distribution and services Group, today announces its trading statement for the period since 30 June 2024.

Group revenue in the quarter grew by 5.4% at constant exchange rates. Underlying revenue, which is organic revenue adjusted for trading days1declined by 1.2%, an expected improvement in trading compared to the prior quarter as underlying revenue trends continue to strengthen. Improved performance through the quarter in our US foodservice redistribution business supported volume growth in North America, with the Group overall delivering modest volume growth year-on-year. Acquisitions contributed growth of 6.8% at constant exchange rates. Overall, at actual exchange rates, Group revenue grew by 2.0%. Operating margin over the quarter was in line with expectations, supporting our 2024 outlook.

The Group's full year guidance remains unchanged. The Group continues to expect to deliver robust revenue growth, at constant exchange rates, driven by acquisitions already completed in 2024; with a small decline in underlying revenue. We continue to expect adjusted operating profit in 2024 to show a strong increase in comparison with 2023, at constant exchange rates, with Group operating margin expected to be moderately above the level reported for 2023.

In August 2024, we made a commitment to allocate c.£700 million per annum, primarily to be invested in value-accretive acquisitions and, if required, returns of capital in each of the three years ending 31 December 2027, which is intended to steadily return Bunzl to its target leverage range by the end of 2027. We also initiated a £250 million buyback with immediate effect with an expectation of announcing a further buyback at our 2024 preliminary results. Since the results we have executed approximately £100 million of the £250 million buyback, and as set out below, continued to invest in value-accretive acquisitions.

In August, Bunzl completed the acquisition of Cermerón, a regional distributor of cleaning & hygiene products to foodservice and hospitality customers in Southern Spain, which enhances Bunzl's regional strength in these sectors. The business generated revenue of EUR 13 million (£11 million) in 2023.

In September, Bunzl completed the acquisition of Cubro Group ("Cubro"), the leading distributor of mobility aids and clinical furniture to the aged care, community care, and hospital markets in New Zealand. This fast-growing business expands our offering in the healthcare market, and generated NZD 92 million (£44 million) of revenue in the year to March 2024.

In September, Bunzl completed the acquisition of DBM Medical Group ("DBM"), a specialist distributor of orthopaedic surgery products in New Zealand. DBM complements our growing healthcare business in the region and generated NZD 16 million (£7 million) of revenue in the year to June 2024.

In October, Bunzl completed the acquisition of Arrow County Holdings Limited ("Arrow"), a distributor of cleaning and hygiene products in the UK, with a strong own brand portfolio. The business complements our existing customer offering and generated revenue of £24 million in 2023.

Commenting on today's announcement, Frank van Zanten, Chief Executive Officer of Bunzl, said:

 

"Bunzl has delivered another period of good growth that demonstrates the ongoing strength of our compounding strategy and resilient business model. I am pleased to see continued momentum in underlying revenue performance and the extension of this year's acquisition success, with 11 acquisitions announced, and our pipeline remaining active. We welcome Cubro, DBM, Cermerón and Arrow, strengthening our growing position in New Zealand's healthcare market, enhancing our regional position in Spain, and complementing our own brand portfolio in the UK. Our initial £250 million share buyback is also well underway, and I reiterate our commitment to allocate c.£700 million per annum, primarily to invest in value-accretive acquisitions and, if required, returns of capital in each of the three years to 2027."

Enquiries:

 

Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Sunita Entwisle, Head of Investor Relations and Communications

Tel: +44 (0)20 7725 5000

Teneo

Martin Robinson

Olivia Peters

Tel: +44 (0)20 7353 4200

1. Net of the benefit of growth in excess of 26% per annum in hyperinflationary economies, which contributed a small decrease of 0.2%. Trading days had a negligible impact over the period.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBXBDGLGDDGSX
Date   Source Headline
3rd Jun 202610:45 amRNSDirector/PDMR Shareholding
1st Jun 202610:15 amRNSTotal Voting Rights
1st Jun 202610:00 amRNSAdmission to Trading
8th May 20264:13 pmRNSDirector/PDMR Shareholding
7th May 20262:43 pmRNSDirector/PDMR Shareholding
6th May 202610:05 amRNSDirector/PDMR Shareholding
1st May 202611:15 amRNSTotal Voting Rights
22nd Apr 20264:15 pmRNSResult of AGM
22nd Apr 20267:00 amRNSTrading Statement
13th Apr 20264:00 pmRNSDirector/PDMR Shareholding
9th Apr 202612:01 pmRNSDirector/PDMR Shareholding
1st Apr 20264:00 pmRNSDirector/PDMR Shareholding
1st Apr 202611:00 amRNSTotal Voting Rights
31st Mar 20264:50 pmRNSDirector/PDMR Shareholding
20th Mar 20262:28 pmRNSDirector/PDMR Shareholding
18th Mar 20265:26 pmRNSDirector/PDMR Shareholding
17th Mar 20264:20 pmRNSAnnual Financial Report
16th Mar 20263:00 pmRNSDirector/PDMR Shareholding
16th Mar 20263:00 pmRNSDirector/PDMR Shareholding
11th Mar 20264:00 pmRNSDirector/PDMR Shareholding
11th Mar 20264:00 pmRNSDirector/PDMR Shareholding
10th Mar 20263:30 pmRNSDirector Declaration
10th Mar 20263:30 pmRNSDirector Declaration
9th Mar 202610:20 amRNSDirector/PDMR Shareholding
5th Mar 20265:15 pmRNSDirector/PDMR Shareholding
4th Mar 20264:00 pmRNSDirector/PDMR Shareholding
3rd Mar 20264:45 pmRNSDirector/PDMR Shareholding
2nd Mar 202611:00 amRNSTotal Voting Rights
2nd Mar 202610:00 amRNSDividend Declaration
2nd Mar 20267:00 amRNSFinal Results
3rd Feb 20265:00 pmRNSDirector/PDMR Shareholding
2nd Feb 202612:45 pmRNSTotal Voting Rights
13th Jan 20265:00 pmRNSDirector/PDMR Shareholding
7th Jan 20265:15 pmRNSDirector/PDMR Shareholding
6th Jan 202611:15 amRNSDirector/PDMR Shareholding
2nd Jan 202610:45 amRNSTotal Voting Rights
17th Dec 20257:00 amRNSTrading Statement
3rd Dec 202512:00 pmRNSDirector/PDMR Shareholding
1st Dec 202511:00 amRNSTotal Voting Rights
27th Nov 20259:00 amRNSAdditional Listing
26th Nov 20253:34 pmRNSPublication of Admission Particulars.
21st Nov 20255:30 pmRNSHolding(s) in Company
17th Nov 20255:34 pmRNSHolding(s) in Company
13th Nov 20259:00 amRNSAdditional Listing
5th Nov 20259:45 amRNSDirector/PDMR Shareholding
3rd Nov 20254:00 pmRNSHolding(s) in Company
3rd Nov 20253:29 pmRNSTotal Voting Rights
3rd Nov 20259:30 amRNSBlock listing Interim Review
3rd Nov 20257:00 amRNSTransaction in Own Shares
31st Oct 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.